Acute Lymphoblastic Leukemia in Children: Recent Findings

ALL is the most common cancer in children and is among the most curable of the pediatric malignancies. Many clinical, biological, genetic, and molecular features have been identified as having prognostic significance in the outcome of patients with ALL. Prognostic features play a critical role in directing therapy for ALL and as scientific and treatment advances are made, this area of investigation changes rapidly. This session will discuss the importance of prognostic factors that may influence the treatments used for patients with ALL, as well as review treatment protocols designed to reduce toxicity while preserving efficacy for ALL patients.

Learning Objectives
At the end of this educational activity, participants should be able to

  1. Identify prognostic factors that influence treatment and outcomes for patients with ALL
  2. Discuss treatment protocols designed to reduce toxicity while preserving efficacy for patients with ALL

Faculty Listing
Nobuko Hijiya, MD
Associate Professor of Pediatrics
Northwestern University Feinberg School of Medicine;
Hematology, Oncology and Stem Cell Transplant
Ann & Robert H. Lurie Children’s Hospital of Chicago
Chicago, Illinois

Disclosures of Relevant Financial Relationships
In accordance with the ACCME Standards for Commercial SupportSM, OptumHealth Education requires all those involved in the development of activity content to disclose their relevant financial relationships. An individual has a relevant financial relationship if such person (or their spouse/partner) has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the activity content over which the individual has control.
OptumHealth Education ensures that the content is independent of commercial bias.

Financial Relationship Key
A-Advisory Board
C-Consultant
E-Employee
G- Grant/Research Support
I-Stocks and Other Ownership Interests
S-Speakers’ Bureau
O-Other Financial or Material Support
N-Nothing to disclose
X-Will disclose onsite
Resolution Key
R1-Restricted to Best Available Evidence
R2-Removed/Altered Financial Relationship
R3-Refrain from Recommending Products or Services
R4-Peer Review of Presentation
R5-Ensure that content is independent of commercial bias
R6-Recommend an alternative speaker for this topic for the planning committee’s consideration
N/A-Not Applicable

 

Last Name

First Name

Disclosure

Resolution

Role

Abecassis

Michael

N

N/A

Planner

Chart-Hart

Sarah

UnitedHealth Group (E) (I)

R5

Planner

Gleason

Rebecca

UnitedHealth Group (E) (I)

R5

Planner

LeMaistre

C. Fred

N

N/A

Planner

Mulligan

David C.

N

N/A

Planner

Roberts

John P.

Gilead (C)

R5

Planner

Rome

Arlene

UnitedHealth Group (E) (I)

R5

Planner

Sendaydiego

Anne M.

N

N/A

Planner

Hijiya

Nobuko

Pfizer, Sigma Tau (A); Jazz Pharma (C); Sanofi (C) (O)

R1, R3

Faculty

Method of Participation
There are no fees for participating in or receiving credit for this activity.
For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

Participants will receive a certificate upon successful completion of the activity, which includes the following:

  • Completing the entire activity
  • Completing the Pre- and Post-Activity Assessments, Activity Evaluation, and Application for Certificate of Credit forms

You must be logged into your account to participate in this activity. Get started by clicking “Begin” and viewing the “CE Info”; then follow the prompts at the bottom of the screen. At the end of the activity, you will be able to view, save, or print your certificate of participation. The Area of Practice you indicated in your profile corresponds with your certificate type. A complete listing of all of your activities can be found under “My Account”, “My Activities.”

Method for Calculating CE Credit
CE credit was calculated by the complexity of content.

Provided By
This activity is provided by OptumHealth Education.

Commercial Support
This activity is supported by an educational grant from Onyx Pharmaceuticals.

Hardware/Software Requirements
To view this activity you will need Internet Explorer 7.0+ or Firefox 3.0+ with Windows Media Player 9+, RealPlayer 12+, or Adobe Flash Player 9+. Be sure to disable your pop-up blocking software prior to the beginning of this activity.

Target Audience

This activity is designed to meet the educational needs of physicians, nurses, pharmacists, case managers, and other health care professionals.

Activity summary
Available credit: 
  • 0.75 ACPE - Pharmacist
  • 0.75 AMA
  • 0.75 ANCC
  • 0.75 Attendance
  • 0.75 CCMC - General
Activity opens: 
11/03/2014
Activity expires: 
11/03/2016
Rating: 
0

Available Credit

  • 0.75 ACPE - Pharmacist
  • 0.75 AMA
  • 0.75 ANCC
  • 0.75 Attendance
  • 0.75 CCMC - General
Please login to register.